After tanking on Novo's "Wegovy Pill" release, Eli Lilly shares reversed course. See why investors may like its acquisition of Ventyx Biosciences.
Track healthcare’s 2026 setup: GLP-1 drug adoption, a valuation gap vs. tech, and why VHT offers broad exposure with low fees and dividends.
Novo Nordisk shares inch higher as the pharma giant announces an oral Wegovy partnership with Amazon Pharmacy. Here’s why NVO stock is worth owning at current levels.
PLAINSBORO, N.J.and BAGSVÆRD, Denmark , Jan. 5, 2026 /PRNewswire/ -- Wegovy ® pill is now available, providing those seeking help with their weight the revolutionary science of GLP-1 medicine...
Novo Nordisk is down big in 2025, but hope is far from lost in 2026. The company's newly approved weight-loss pill could be the remedy that shares need.
Eli Lilly has been a huge winner in the last few months of 2025. New clinical data support its outlook in 2026, with large potential catalysts on the horizon.
As Novo Nordisk’s FDA-approved Wegovy pill sets up a high-stakes comeback, should NVO be back on investors’ radar now?
A month after acquiring obesity biotech Metsera, Pfizer's expanding in the weight loss drug market after signing a licensing agreement for a weight loss pill.
Three stocks flashing a golden cross—Sun Communities, Darling Ingredients, and Wave Life Sciences—may offer strong upside potential heading into 2026
High short interest in critical tech names points to a robust rebound for these stocks and others in 2026. The Q4 reporting cycle is a likely catalyst.